Exact Sciences Corporation logo
Exact Sciences Corporation EXAS
$ 103.57 0.29%

Annual report 2025
added 02-13-2026

report update icon

Exact Sciences Corporation Financial Statements 2011-2026 | EXAS

Annual Financial Statements Exact Sciences Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

19.5 B 9.27 B 11.2 B 10.9 B 13.1 B 20.7 B 12.3 B 10.7 B 5.73 B 1.85 B 605 M 2.18 B 902 M 644 M 478 M

Shares

189 M 184 M 180 M 176 M 171 M 151 M 131 M 122 M 116 M 102 M 92.1 M 80.2 M 67.5 M 59.5 M 52.5 M

Historical Prices

103 50.3 62.3 61.8 76.4 137 93.3 90.1 49.7 18.9 6.57 27.2 13 11 9.34

Net Income

-208 M -1.03 B -204 M -624 M -596 M -824 M -84 M -175 M -114 M -167 M -158 M -100 M -46.5 M -52.5 M -28.7 M

Revenue

3.25 B 2.76 B 2.5 B 2.08 B 1.77 B 1.49 B 876 M 454 M 266 M 99.4 M 39.4 M 1.8 M 4.14 M 4.14 M 4.16 M

Cost of Revenue

984 M 840 M 738 M 661 M 459 M 354 M 217 M 117 M 78.3 M 45.2 M 24.5 M 4.32 M - - 24 K

Gross Profit

2.26 B 1.92 B 1.76 B 1.42 B - - 660 M 336 M 187 M 54.2 M 14.9 M -2.53 M 4.14 M 4.14 M 4.14 M

Operating Income

-206 M -1.05 B -215 M -594 M -856 M -768 M -234 M -159 M -118 M -169 M -159 M -101 M -46.8 M -52.6 M -28.8 M

Interest Expense

- - - - 18.6 M 67.9 M 199 M 36.8 M 206 K -213 K 6 K 51 K 69 K 41 K 21 K

EBITDA

-81.4 M -929 M -101 M -493 M -761 M -698 M -218 M -136 M -103 M -157 M -155 M -98.9 M -45.3 M -51.7 M -28.4 M

Operating Expenses

2.47 B 2.98 B 2.06 B 2 B - - 893 M 496 M 305 M 223 M 174 M 98 M 50.9 M 56.8 M 33 M

General and Administrative Expenses

889 M 782 M 800 M 663 M 801 M 481 M 540 M 296 M 186 M 138 M 106 M 65.2 M 22.7 M 14.4 M 8.14 M

All numbers in USD currency

Quarterly Income Statement Exact Sciences Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

189 M 189 M 187 M 186 M 185 M 184 M 182 M 181 M 181 M 180 M 179 M 178 M 177 M 176 M 174 M 174 M 172 M 171 M 169 M 156 M 150 M 150 M 148 M 140 M 130 M 129 M 126 M 123 M 123 M 122 M 121 M 120 M 119 M 113 M 111 M 109 M 105 M 97.9 M 97.2 M 96.4 M 94.4 M 88.9 M 88.7 M 84.7 M 82.9 M 82 M 71 M 70.8 M 70.6 M 64.7 M 63.8 M 63.6 M 60.5 M 57 M 56.7 M 53.6 M 52.4 M 52 M 51.9 M

Net Income

-19.6 M -1.18 M -101 M - -38.2 M -15.8 M -110 M - 794 K -81 M -74.2 M - -149 M -166 M -181 M -221 M -167 M -177 M -31.2 M -418 M -203 M -68.1 M -135 M 78 M -40.5 M -38.5 M -82.9 M -54 M -45.4 M -36.4 M -39.4 M -21.8 M -26.9 M -30.8 M -34.9 M -37.2 M -37.8 M -44.8 M -47.5 M -40 M -42.9 M -39.1 M -35.8 M -32.4 M -32.1 M -19.4 M -16.1 M -12.2 M -11.2 M -12.3 M -10.9 M -14 M -13 M -14.8 M -10.6 M -9.9 M -7.77 M -6.62 M -4.37 M

Revenue

851 M 811 M 707 M - 709 M 699 M 638 M - 628 M 622 M 602 M - 523 M 522 M 487 M 474 M 456 M 435 M 402 M 466 M 408 M 269 M 348 M 296 M 219 M 200 M 162 M 143 M 118 M 103 M 90.3 M 87.4 M 72.6 M 57.6 M 48.4 M - - - - - 12.6 M 8.12 M 4.27 M - 294 K 294 K 294 K 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M

Cost of Revenue

267 M 249 M 206 M - 217 M 211 M 191 M - 169 M 157 M 157 M - 148 M 145 M 135 M 119 M 116 M 114 M 110 M 99.8 M 95.1 M 77.9 M 81.6 M 70.4 M 52.3 M 51.1 M 42.8 M 37.8 M 29.7 M 26.6 M 22.6 M 23.5 M 20.7 M 18 M 17 M 13.9 M 12.2 M 10.1 M 9.06 M 7.67 M 7.53 M 5.09 M 4.21 M 3.4 M 924 K - - - - - - - - - - 6 K 6 K 6 K 6 K

Gross Profit

584 M 562 M 501 M - 491 M 488 M 446 M - - - - - - - - 334 M 319 M 300 M 272 M 346 M 293 M 170 M 246 M 213 M 166 M 148 M 119 M 105 M 88.3 M 76 M 67.4 M 63.9 M 51.8 M 39.7 M 31.4 M 21.4 M 15.9 M 11.1 M 5.78 M 6.75 M 5.1 M 3.02 M 54 K -1.9 M -924 K 294 K 294 K 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.04 M 1.03 M 1.04 M 1.03 M

Operating Income

-25.5 M -2.15 M -96 M - -39.4 M -26.3 M -107 M - 6.85 M -76.9 M -77.1 M - -138 M -160 M -177 M - -162 M -172 M -301 M - -203 M -67 M -82.4 M -96.1 M -35.7 M -33.9 M -68.1 M -49.3 M -40.9 M -32.7 M -36.5 M -23 M -28.4 M -31.4 M -35.5 M -37.7 M -38.3 M -45.1 M -47.9 M -40.4 M -43.3 M -39.4 M -36 M -32.6 M -32.2 M -19.6 M -16.2 M -12.3 M -11.2 M -12.4 M -10.9 M -14 M -13 M -14.9 M -10.7 M -9.94 M -7.84 M -6.64 M -4.4 M

Interest Expense

- - - - -9.61 M 111 K -7.94 M - -7.87 M -7.82 M 4.11 M - -5.24 M -4.51 M -4.48 M - -4.68 M -4.65 M -4.62 M - 23.6 M 22.9 M 25.2 M -13.7 M 13.2 M 12.7 M 22 M -11 M 10.7 M 8.6 M -6.51 M -51 K -51 K -54 K -50 K -52 K -54 K -53 K 54 K -62 K -40 K 107 K 11 K 11 K 12 K 13 K 15 K 16 K 16 K 18 K 19 K 20 K 11 K 5 K 5 K 6 K 5 K 5 K 5 K

EBITDA

6.16 M 29 M -66 M - -9.1 M 3.44 M -76.1 M - 36.1 M -49.4 M -50.3 M - -113 M -134 M -154 M - -140 M -150 M -280 M - -150 M -33.4 M -66.4 M -82.3 M -13.8 M -20.4 M -61.7 M -48.6 M -26.6 M -23.9 M -32.2 M -23 M -27.8 M -31.1 M -35.4 M -37.7 M -38.1 M -45 M -45.4 M -40.4 M -43.3 M -39.4 M -34.4 M -32.6 M -29.9 M -18.2 M -15.5 M -12.3 M -10.3 M -11.7 M -10.6 M -14 M -12.3 M -14.5 M -10.5 M -9.94 M -7.58 M -6.5 M -4.34 M

Operating Expenses

609 M 565 M 597 M - 534 M 518 M 553 M - - - - - - - - 555 M 481 M 471 M 572 M 761 M 496 M 237 M 328 M 309 M 202 M 182 M 187 M - 129 M 109 M 104 M - 80.3 M 71.1 M 66.9 M - 54.2 M 56.2 M 53.7 M - 48.4 M 42.4 M 36.1 M - 31.3 M 19.6 M 16.5 M - 12.3 M 13.4 M 11.9 M - 14 M 15.9 M 11.7 M - 8.88 M 7.68 M 5.44 M

General and Administrative Expenses

241 M 209 M 221 M - 194 M 178 M 220 M - 217 M 238 M 217 M - 192 M 182 M 170 M - 187 M 168 M 268 M - 116 M 107 M 114 M 144 M 80.5 M 63.7 M 63.8 M 56.3 M 46.7 M 39.5 M 35.5 M 33.6 M 30.8 M 24.6 M 20.1 M 21.5 M 20.3 M 17.3 M 17.8 M 15.9 M 15.4 M 13.7 M 13 M 10.6 M 8.99 M 6.23 M 4.59 M 3.69 M 3.69 M 3.63 M 2.65 M 2.82 M 2.55 M 2.39 M 2.14 M 2.21 M 1.95 M 1.83 M 2.15 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Exact Sciences Corporation EXAS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Exact Sciences Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 98.33 0.9 % $ 8.11 B irlandaIrlanda
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 13.71 -0.22 % $ 99.4 M israelIsrael
Charles River Laboratories International Charles River Laboratories International
CRL
$ 155.46 1.83 % $ 7.71 B usaUSA
Bioventus Bioventus
BVS
$ 8.62 0.23 % $ 574 M usaUSA
DexCom DexCom
DXCM
$ 64.24 -1.56 % $ 25.1 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Castle Biosciences Castle Biosciences
CSTL
$ 25.56 0.95 % $ 710 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 17.01 3.4 % $ 906 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Guardant Health Guardant Health
GH
$ 85.49 1.75 % $ 10.7 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Fulgent Genetics Fulgent Genetics
FLGT
$ 14.77 0.61 % $ 447 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Biodesix Biodesix
BDSX
$ 17.88 -6.63 % $ 2.32 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.83 -1.05 % $ 91.8 K usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 187.32 0.57 % $ 134 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 164.72 1.1 % $ 28.3 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Illumina Illumina
ILMN
$ 118.94 2.92 % $ 18.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 199.7 -0.46 % $ 22.2 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Agilent Technologies Agilent Technologies
A
$ 111.51 -0.06 % $ 33.9 B usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.11 -0.89 % $ 1.41 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 9.0 -0.99 % $ 255 M israelIsrael
Neogen Corporation Neogen Corporation
NEOG
$ 9.09 -2.78 % $ 1.97 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 16.52 0.12 % $ 370 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.33 4.72 % $ 399 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
- - $ 79.8 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 450.41 1.48 % $ 13 B usaUSA
Celcuity Celcuity
CELC
$ 114.22 3.11 % $ 4.51 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 173.74 0.49 % $ 24.2 B schweizSchweiz
Personalis Personalis
PSNL
$ 6.72 1.97 % $ 398 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 7.88 -1.25 % $ 1.01 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Natera Natera
NTRA
$ 187.85 -1.29 % $ 18.5 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 13.42 0.71 % $ 3.81 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.19 2.59 % $ 826 M usaUSA